Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA,
Curr Oncol Rep. 2013 Oct;15(5):500-8. doi: 10.1007/s11912-013-0337-1.
Ipilimumab, an anti-cytotoxic T-lymphocyte antigen 4 antibody, was the first therapy demonstrated to improve overall survival in melanoma. Since ipilimumab's approval by the FDA in 2011, a wealth of data has amassed, helping clinicians to optimize its use. We have learned how to mitigate the adverse effects of ipilimumab, identified its effects in melanoma subpopulations such as those with brain metastases, uveal melanoma, and mucosal melanoma, discovered potential biomarkers of activity, and investigated its use in combination with other therapeutic modalities. These discoveries have paved the way for rapid development of second-generation immunomodulatory antibodies such as inhibitors of the programmed cell death 1 receptor axis. These new agents hold promise as monotherapy, but perhaps the greatest allure lies in the possibility of combining these agents in synergistic multidrug regimens.
依匹单抗是一种抗细胞毒性 T 淋巴细胞相关抗原 4 抗体，是首个被证实能提高黑色素瘤总生存期的疗法。自 2011 年 FDA 批准依匹单抗以来，大量数据不断涌现，帮助临床医生优化其使用。我们已经了解如何减轻依匹单抗的不良反应，确定了其在脑转移、葡萄膜黑色素瘤和黏膜黑色素瘤等黑色素瘤亚群中的作用，发现了潜在的疗效生物标志物，并研究了其与其他治疗方式联合应用的效果。这些发现为第二代免疫调节抗体（如程序性细胞死亡 1 受体轴抑制剂）的快速发展铺平了道路。这些新药物作为单药治疗具有很大的潜力，但最大的吸引力可能在于这些药物联合应用于协同多药方案的可能性。
